Laurus Labs to focus on formulations to derive significant revenue

04 Oct 2017 Evaluate

Laurus Labs is planning to focus on formulations to derive significant revenue from the segment. In this regards, the company is investing Rs 300 crore in formulations and Active Pharmaceutical Ingredients (APIs) facilities in Visakhapatnam, out of which Rs 150 crore has already been spent. The remaining will be spent before the end of the current financial year.

Last month, Laurus had received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its Finished Dosage Formulations (FDF) and API manufacturing plant, Unit 2, located at Achutapuram, Vishakhapatnam.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs Share Price

491.90 6.75 (1.39%)
31-Oct-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1849.05
Dr. Reddys Lab 1274.25
Cipla 1553.20
Lupin 2184.00
Zydus Lifesciences 1001.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.